RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
  • EMA Confirms Safety of Combined Contraceptives

    EU regulators have declared that they have found no new evidence that combined contraceptives present a greater safety risk to women than is currently known, a response they said was called for after "growing media reports" raised questions about the safety of the products. Combined contraceptive medications, such as Bayer's Yasmin (drospirenone and ethylestradiol), have been associated with "very rare" thromboembolisms, and are closely monitored by both EU and US regula...
  • Consumer Advocacy Group Fires Back at FDA Over Transparency of Advisory Committees

    The consumer advocacy group Project on Government Oversight (POGO) is re-engaging the US Food and Drug Administration (FDA) on whether a panel of experts convened by the agency to review the safety of a class of oral contraceptives was sufficiently independent of conflicts of interest. The entire incident is the result of a January 2012 investigation by the Wall Street Journal into an FDA advisory committee charged with reviewing birth control products containing dro...
  • New Safety Warning Issued For Popular Birth Control Product, Potentially Rekindling Controversy

    The US Food and Drug Administration (FDA) issued an updated safety warning 10 April about birth control products containing drospirenone-a synthetic version of the hormone progesterone-saying the hormone may be associated with a higher risk for blood clots than other progesterone-based pills. Some studies highlighted by FDA showed a three-fold increase in the risk of developing a blood clot, though FDA admitted "it is unclear whether the increased risk seen for blood clo...